Understanding Iqirvo and Livdelzi in Primary Biliary Cholangitis
Recent months have marked a significant turning point in the treatment of primary biliary cholangitis (PBC) with the approval of Ipsen’s Iqirvo (elafibranor) and Gilead’s Livdelzi (seladelpar). Both of these therapies are oral peroxisome proliferator-activated receptor (PPAR) treatments, representing the most substantial advancements in PBC management in nearly a decade. They have been approved for use alongside ursodeoxycholic acid (UDCA) in adults who do not respond adequately to UDCA, or as standalone treatments for those who cannot tolerate UDCA.
Physician Preferences and Market Insights
In the month leading up to Iqirvo’s approval, Spherix Global Insights conducted a survey among gastroenterologists and liver specialists to understand their views on the PBC treatment pipeline. The results revealed a clear preference for Livdelzi over Iqirvo, with nearly half of the participating specialists choosing the Gilead treatment as their top choice in development. In contrast, less than a third expressed support for Ipsen’s offering. This preference for Livdelzi was largely due to its promising efficacy data and its effectiveness in alleviating pruritus, a chronic itch frequently experienced by PBC patients. One physician noted, "Livdelzi seems to meet its primary endpoint the highest out of all drugs with the least adverse events and shows some improvement in helping with itching (pruritus)."
Insights from the Launch Dynamix™ Service
As part of the Launch Dynamix™ service, Spherix will meticulously monitor the uptake of both Iqirvo and Livdelzi during the first eighteen months following their launch. Initial findings for Iqirvo indicated that about three-quarters of the participating specialists were aware of its approval, recognizing it as a significant improvement over existing PBC treatment options. Furthermore, just one month after its launch, half of the respondents reported either currently trying or planning to try Iqirvo within the next three months.
Competitive Landscape and Ongoing Evaluation
Although Iqirvo has demonstrated strong indicators for a successful launch, the competitive landscape is shifting with the introduction of Livdelzi, which may affect future perceptions and adoption rates. Spherix will continue to observe the launches of both products, analyzing the competitive dynamics and their implications for overall treatment strategies. The Launch Dynamix™ service is designed to provide thorough evaluations of these factors.
About Spherix Global Insights
Spherix is a prominent independent market intelligence and advisory firm that delivers commercial insights to the global life sciences sector across the brand lifecycle. Their experienced team offers an unbiased and comprehensive perspective on the rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Clients of Spherix benefit from the extensive knowledge of the Spherix Physician Community, allowing them to stay ahead in their fields.
As a trusted advisor and thought leader in the industry, Spherix’s exceptional market insights and advisory services empower clients to make informed decisions and identify growth opportunities. For more information about Spherix Global Insights, interested parties can visit their website or connect with them on LinkedIn to learn more about their research and services.
Frequently Asked Questions
What is Iqirvo and what condition does it treat?
Iqirvo, also known as elafibranor, is a treatment approved for patients suffering from primary biliary cholangitis (PBC) and is used in conjunction with ursodeoxycholic acid (UDCA) or as monotherapy.
How does Livdelzi compare to Iqirvo in terms of physician preference?
Recent surveys indicated that many physicians favored Livdelzi over Iqirvo, citing its efficacy data and reduced adverse event profiles as key reasons for preference.
What is the Launch Dynamix™ service by Spherix?
Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products, tracking their uptake and evaluating competitive dynamics for up to 18 months post-launch.
How are both Iqirvo and Livdelzi expected to perform in the market?
While Iqirvo has had a strong launch, the competitive entry of Livdelzi could influence future market dynamics and the adoption rate of these treatments among specialists.
How does Spherix Global Insights support the life sciences industry?
Spherix provides comprehensive market intelligence and advisory services that help life sciences companies make informed decisions and leverage growth opportunities in the evolving specialty markets.
